The extremely low efficiency of human embryonic stem cell (hESC) derivation using somatic cell nuclear transfer (SCNT) limits potential application. Blastocyst formation from human SCNT embryos occurs at a low rate and with only some oocyte donors. We previously showed in mice that reduction of histone H3 lysine 9 trimethylation (H3K9me3) 
SUMMARY
The extremely low efficiency of human embryonic stem cell (hESC) derivation using somatic cell nuclear transfer (SCNT) limits potential application. Blastocyst formation from human SCNT embryos occurs at a low rate and with only some oocyte donors. We previously showed in mice that reduction of histone H3 lysine 9 trimethylation (H3K9me3) through ectopic expression of the H3K9me3 demethylase Kdm4d greatly improves SCNT embryo development. Here we show that overexpression of a related H3K9me3 demethylase KDM4A improves human SCNT, and that, as in mice, H3K9me3 in the human somatic cell genome is an SCNT reprogramming barrier. Overexpression of KDM4A significantly improves the blastocyst formation rate in human SCNT embryos by facilitating transcriptional reprogramming, allowing efficient derivation of NT-ESCs using adult Age-related Macular Degeneration (AMD) patient somatic nuclei donors. This conserved mechanistic insight has potential applications for improving SCNT in a variety of contexts, including regenerative medicine.
INTRODUCTION
The differentiated somatic cell genome can be reprogramed back into an embryonic state when the nucleus is exposed to the molecular milieu of the oocyte cytoplasm via somatic cell nuclear transfer (SCNT) (Gurdon, 1962) , thereby enabling the generation of pluripotent embryonic stem cells (ESCs) from terminally-differentiated somatic cells (Wakayama et al., 2001) . Because SCNT derived ESCs (NT-ESCs) are genetically autologous to the nuclear donor somatic cells, SCNT has great potential in therapeutic and regenerative medicine, including disease modeling and cell/tissue replacement therapy (Hochedlinger and Jaenisch, 2003; Yang et al., 2007) . Thus, SCNT can be used to fix mitochondria gene-related defects, which cannot be done through transcription factor-based reprogramming (Ma et al., 2015) . Despite the great potential of human NT-ESCs, technical difficulties makes its application to human therapeutics extremely difficult (French et al., 2008; Noggle et al., 2011; Simerly et al., 2003) .
The first NT-ESCs were generated by the Mitalipov group using differentiated fetal and infant fibroblasts as nuclear donor (Tachibana et al., 2013) . Using their optimized conditions, we and others succeeded in deriving human NT-ESCs from adult and aged patient somatic cells Yamada et al., 2014) . However, derivation of NT-ESCs still remains a very difficult task due to the extremely low rate of SCNT embryos to develop to the blastocyst stage. Currently only oocytes with the highest quality from certain females can support the development of SCNT embryos to the blastocyst stage Tachibana et al., 2013) , limiting the useful oocyte donor pools.
The poor developmental potential of SCNT embryos is not limited to human, but is also commonly observed in all examined mammalian species (Rodriguez-Osorio et al., 2012) .
Through comparative transcriptomic and epigenomic analyses of mouse in vitro fertilization (IVF) and SCNT embryos, we have recently revealed that histone H3 lysine 9 trimethylation (H3K9me3) in the donor somatic cell genome functions as a barrier preventing transcriptional reprogramming by SCNT, leading to failure of zygotic genome activation (ZGA) and preimplantation development . Importantly, we demonstrated that this epigenetic barrier could be removed by ectopically overexpressing mouse Kdm4d, an H3K9me3 Chung et al. 4 demethylase. Removal of H3K9me3 facilitates ZGA and consequently improves development of mouse SCNT embryos to reach the blastocyst stage, leading to an increased rate of mouse NT-ESC establishment . These findings prompted us to ask whether the principle we discovered in mouse can be applied to human SCNT.
Here we report that somatic cell H3K9me3 also serves as a barrier in human SCNT reprogramming. We demonstrate that KDM4A overexpression significantly improves human SCNT embryo development, allowing efficient derivation of patient-specific NT-ESCs using oocytes obtained from donors whose oocytes failed to develop to blastocyst without the help of KDM4A overexpression. Thus, our study expands the usability of oocyte donors and establishes the histone demethylase-assisted SCNT as a general method for improving mammalian SCNT for reproductive and therapeutic cloning.
Chung et al.
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RESULTS
Identification of reprogramming resistant regions in 8-cell human SCNT embryos
Human zygotic genome activation (ZGA) takes place during the late 4-cell to the late 8-cell stages (Niakan et al., 2012) (Figure 1A ). To identify the genomic regions activated during ZGA of normal human IVF embryos, we analyzed published human preimplantation embryo RNAsequencing (RNA-seq) datasets (Xue et al., 2013) and identified 707 genomic regions ranging 20-160 kb in sizes (Table S1 ) that were activated at least 5-fold at the 8-cell stage compared to the 4-cell stage ( Figure 1B ).
To determine whether ZGA takes place properly in human SCNT, we collected late 8-cell stage embryos (5/group), derived either from SCNT or IVF, and performed RNA-seq ( Figure 1A ). In parallel, we also performed RNA-seq of the donor dermal fibroblast cells (DFB-8, see method).
Analysis of the 707 genomic regions defined above ( Figure 1B , Table S1) indicates that the majority of the ZGA regions are activated in the SCNT embryos compared to those in donor fibroblasts ( Figure 1C) . However, the level of activation is not comparable to that in IVF embryos ( Figure 1C ). Of the 707 genomic regions, 169 were activated at a level comparable to those in IVF embryos (FC <= 2, IVF vs SCNT), and were thus termed fully-reprogrammed regions (FRRs) following our previous definition . Similarly, 220 regions were partially activated (2< FC <= 5) in SCNT compared to IVF embryos and were termed "partially reprogrammed regions" (PRRs). However, the remaining 318 regions (Table S2) , termed "reprogramming resistant regions" (RRRs), failed to be activated in SCNT embryos (FC > 5). Thus, comparative transcriptome analysis allowed us to identify 318 RRRs that were refractory to transcriptional reprogramming in human 8-cell SCNT embryos.
The heterochromatin features of RRRs are conserved in human somatic cells
We next asked whether the human RRRs possess the heterochromatin features like that of the mouse RRRs. Analysis of the publically-available ChIP-seq datasets of eight major histone modifications from human fibroblast cells (Bernstein et al., 2012; The Encode Consortium Project, 2011) revealed specific enrichment of H3K9me3 in human RRRs ( Figures 1D and S1A ).
The enrichment of H3K9me3 is unique to RRRs, as a similar enrichment was not observed in Chung et al. 6 FRRs or PRRs ( Figures 1D and S1A ). Similar analysis also revealed the enrichment of H3K9me3 at RRRs in K562 erythroleukemic cells, Hsmm skeletal muscle myoblasts, and Mcf7 breast adenocarcinoma cells (Figures 1E and S1B) , indicating H3K9me3 enrichment in RRRs is a common feature of somatic cells.
Next, we analyzed the DNaseI hypersensitivity of four different somatic cell types using the datasets generated by the ENCODE project. The analysis revealed that RRRs are significantly less sensitive to DNaseI compared to FRR and PRR in all human somatic cell-types analyzed (Figures 1F and S1C) . Consistent with their heterochromatin feature, human RRRs are relatively gene-poor compared to FRRs or PRRs ( Figure S1D ), and are enriched with specific repeat sequences such as LINE and LTR, but not SINE ( Figure S1E ). Collectively, these results indicate that the heterochromatin features of RRRs, enrichment of H3K9me3 and decreased accessibility to DNaseI, are conserved in both mouse and human somatic cells.
Human KDM4A mRNA injection improves development of mouse SCNT embryos
Having established that human RRRs are enriched for H3K9me3, we next asked whether removal of H3K9me3 could help overcome the reprogramming barrier in human SCNT embryos.
We previously demonstrated using mouse SCNT model that the H3K9me3 barrier could be removed by injecting mRNAs encoding the mouse H3K9me3 demethylase, Kdm4d . Before moving into human SCNT model, given that multiple members of the KDM4 family with H3K9me3 demethylase activity exist in mouse and human (Klose et al., 2006; Krishnan and Trievel, 2013; Whetstine et al., 2006) , we were interested in determining whether the effect of Kdm4d in facilitating SCNT reprogramming could be extended to other members of the KDM4 family. In addition, we were also interested in testing whether KDM4 family members could function across species.
To this end, we performed SCNT using cumulus cells of adult female mice as nuclear donors and injected human KDM4A mRNA at 5 hours post-activation (hpa) following the same procedure used in our previous study (Figure 2A ) . Immunostaining revealed that injection of wild-type, but not a catalytic mutant, human KDM4A mRNA greatly reduced H3K9me3 levels in the nucleus of mouse SCNT embryos ( Figure 1B) . Importantly, injection of 7 KDM4A mRNA greatly increased the developmental potential of SCNT embryos with 90.3% of them develop to the blastocyst stage, which is in contrast to the 26% blastocyst formation rate in control ( Figures 2C and 2D , Table S3 ). The extremely high efficiency of blastocyst formation is similar to the 88.6% observed in Kdm4d-injected mouse SCNT embryos .
These results suggest that the reprogramming barrier, H3K9me3 in the somatic cell genome, can be removed by any member of the KDM4 family demethylases as long as it contains H3K9me3 demethylase activity.
KDM4A mRNA injection significantly increases the blastocyst formation rate of human
SCNT embryos
We next asked whether KDM4A mRNA injection could also help overcome the reprogramming barrier in human SCNT using the optimized SCNT conditions including the use of histone deacetylase inhibitor, Trichostatin A (TSA) (Tachibana et al., 2013) . With the future clinical application of KDM4A-assisted SCNT in mind, we used dermal fibroblasts of Age-related Macular Degeneration (AMD) patients (Bressler et al., 1988) as nuclear donors.
To reaffirm the beneficial effect of the KDM4A on human SCNT, we chose oocyte donors whose oocytes failed to develop to the expanded blastocyst in our past attempts using the regular procedures . Following enucleation, a total of 114 MII oocytes collected from four oocyte donors were fused to donor fibroblast cells by HVJ-E. Upon activation, 63 of the reconstructed SCNT oocytes were injected with human KDM4A mRNA and the rest (51) served as non-injected controls ( Figure 2E , Table S4 ). We monitored the developmental process of these SCNT embryos and found that the two groups featured similar cleavage efficiencies to form 2-cell embryos (control: 48/51=94.1%, KDM4A: 56/63=88.9%) ( Table S4 ). As expected, KDM4A mRNA injection did not show any beneficial effect on the developmental rate of SCNT embryos before ZGA finishes at the end of 8-cell stage (68.8% vs 71.4%) ( Figure 2F and Table   S4 ). However, the beneficial effect became clear at the morula stage (16.7% vs 32.1%) ( Figure   2F and Table S4 ). Strikingly, at day 6, 26.8% (15/56) of the KDM4A-injected embryos had successfully reached the blastocyst stage, as compared to only 4.2% (2/48) of control embryos.
On day 7, 14.3% of KDM4A-injected embryos developed to the expanded blastocyst stage, while none of the control embryos developed into this stage ( Figures 2F and 2G) . Importantly, Chung et al. 8 the beneficial effect of KDM4A was observed in all four donors examined ( Figure 2H ). Thus we conclude that KDM4A mRNA injection can improve the developmental potential of human SCNT embryos especially beyond ZGA.
Establishment and characterization of human ESCs derived from KDM4A-injected SCNT blastocysts
We next attempted to derive nuclear transfer ESCs (NT-ESCs) from KDM4A-injected SCNT blastocysts. We obtained a total of eight expanded blastocysts from KDM4A-injected SCNT embryos ( Figure 3A and Table S4 ). After removal of the zona pellucida, the expanded blastocysts were cultured on irradiated mouse embryonic fibroblasts (MEF) in a conventional Mitochondrial DNA sequence analysis revealed that both SNPs of NTK-ESCs matched exactly those of oocyte-donors, but not those of nuclear donors ( Figures 3J and S3C ). Collectively, these results establish the reliability of our SCNT method, and demonstrate that KDM4A mRNA injection improves SCNT-mediated ESC derivation without compromising pluripotency or genomic stability of the established NTK-ESCs.
KDM4A facilitates ZGA of RRRs in 8-cell SCNT embryos
The fact that KDM4A mRNA injection significantly improves SCNT embryo development post To identify candidate gene(s) that might help explain the improved development of KDM4A injected SCNT embryos, we focused our analysis on genes. We identified 206 genes (Table S5) whose expression was significantly up-regulated by KDM4A injection (FPKM > 5, FC > 2).
Gene ontology analysis revealed that these genes were enriched for transcriptional regulation, ribosomal biogenesis and RNA processing ( Figure 4B ), suggesting that dysregulation of these developmentally important machineries might be a cause of developmental arrest of SCNT embryos. Although the function of the majority of the 206 genes in preimplantation development is currently unknown, two of them, UBTFL1 and THOC5 ( Figure 4C ), are known to be required for normal preimplantation development in mice (Wang et al., 2013; Yamada et al., 2009 ).
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Therefore, defective activation of these genes is at least partly responsible for the poor development of human SCNT embryos.
DISCUSSION
After decades of efforts, human NT-ESCs were finally derived recently Tachibana et al., 2013; Yamada et al., 2014) . These advances were mainly due to optimization of SCNT derivation conditions. However, the intrinsic defects in epigenetic reprogramming that cause the developmental arrest of human SCNT embryos have not been identified. In this study, we demonstrate that similar to mouse, H3K9me3 in somatic cell genome presents a barrier for human SCNT reprogramming. Removal of this barrier by overexpressing the H3K9me3 demethylase, KDM4A, facilitates transcriptional reprogramming at ZGA, thereby allowing human SCNT embryos to develop more efficiently to generate blastocysts, from which we successfully established multiple AMD patient-specific NT-ESC lines without compromising genomic stability or pluripotency. Our study thus not only demonstrates that H3K9me3 as a general reprogramming barrier, but also establishes a practical approach for improving cloning efficiency.
It has been well known that the ability of human oocytes to support SCNT embryo development varies greatly among oocyte donors. Indeed, human NT-ESCs can be derived only when highquality oocytes donated by a small group of females were used as recipients Tachibana et al., 2013; Yamada et al., 2014) , although the reason for the dependence on oocyte quality remains elusive. Consistently, oocytes from only one (ID #58) out of the four donors supported SCNT blastocyst formation without KDM4A mRNA injection even under the presence of TSA, which has been reported to enhance blastocyst formation (Tachibana et al., 2013 ) ( Figure 2H and Table S4 ). In contrast, oocytes of all four donors tested supported blastocyst formation when KDM4A mRNAs were injected, indicating that KDM4A can overcome the donor variation problem. Whether KDM4A can improve IVF embryo development remains to be determined.
Although the developmental potential of human SCNT embryos reaching the blastocyst stage was significantly and consistently improved by KDM4A mRNA injection, the magnitude of improvement was not as drastic as that of mice (90% in mice vs. 27% in human). One possible explanation to this species difference is that the quality of human oocytes varies greatly even within the same batch of oocytes derived from a single ovulation, and only a fraction of them have the capacity to support development to blastocyst stage even by IVF, which has a varying success rate of 15-60% (Shapiro et al., 2002; Stone et al., 2014) . This is in clear contrast to mouse IVF where more than 90% of embryos can develop to the blastocyst stage. It is therefore possible that some of the human oocytes that we used in our experiments could not support blastocyst formation even by IVF.
In addition to demonstrating the efficacy of KDM4A in improving human SCNT efficiency and NT-ESC derivation, another important finding of this study is that KDM4A can facilitate both mouse and human SCNT reprogramming. Considering that human KDM4A can function in mouse SCNT embryos to achieve a similar effect as Kdm4d does, it is likely that all members of the KDM4 family can be used to facilitate SCNT as long as they possess H3K9me3 demethylase activity. Given that H3K9me3 in somatic genome functions as a reprogramming barrier in both mouse and human, it is likely that this reprogramming barrier might be conserved in other mammalian species as well. If this is the case, our KDM4-assieted SCNT method should be generally applicable to the cloning of other mammalian species.
In summary, we have established an improved KDM4-assisted SCNT method. Using this method, we derived blastocysts from adult AMD patient cells and subsequently established multiple NTK-ESCs with genomes identical to those of donor patients. This provides unique and important cell sources for understanding AMD as well as for therapeutic drug screening for AMD treatments. Given that the same strategy can be applied to the studies of other human diseases, we anticipate that our study will have a general impact on human therapeutics.
Additionally, since SCNT allows replacement of somatic cell mitochondria with that of recipient oocyte, as we have demonstrated in this study , it provides an opportunity to treat mitochondrial DNA-related diseases. Indeed, a recent study demonstrated that a metabolic syndrome phenotype caused by mtDNA mutation can be corrected by replacing mtDNA through SCNT (Ma et al., 2015) . Thus, our KDM4-assisted SCNT method should be useful for mtDNA-replacement therapies.
Chung et al. For enucleation, oocytes were pre-incubated in Global HTF medium with Hepes (Life Global) containing 0.5 µg/ml cytochalasin B and caffeine (1.25 mM) for 5 minutes. Then, the spindle complex was removed using a PIEZO actuator (Primetech, Japan). Dermal fibroblast cells resuspended in a drop containing HVJ-E extract (Cosmo Bio, USA) were inserted into the perivitelline space of the enucleated oocytes. The reconstructed oocytes were kept in the manipulation medium containing caffeine (1.25mM) until the cell fusion was confirmed, and then the reconstructed oocytes were transferred into Global medium 10% SPS, and incubated for 1-1.5 hours before activation. Activation was carried out by applying electropulses (2X 50µs DC pulses, 2.7 kV/cm) in 0.25M d-sorbitol buffer and 6-DMAP (2 mM, 4 hrs) as previously described (Tachibana et al., 2013) . The activated embryos were transferred to Global 10% SPS medium supplemented with Trichostatin A (TSA, 10nM, Sigma) for 12 hrs, then the embryos were transferred to Global 10% FBS without TSA and cultured for up to 7 days in an incubator with atmosphere of 6% CO2 / 5% O2/ 89% N2 at 37°C. The culture medium was changed on day 3.
For mRNA injection, the activated SCNT embryos were washed and cultured in Global 10% SPS for 1 hr before the KDM4A mRNA injection. Approximately 10 pl of KDM4A mRNA were injected into the SCNT embryos at 5 hours after activation in Hepes-HTF 10% SPS medium using a PIEZO actuator as described previously . More details on donor cell preparation, mRNA preparation, RNA-seq and other procedures can be found in the Supplemental Experimental Procedures.
Identification of human reprogramming resistant regions
A sliding window (size 20 kb, step size 10 kb) was used to assess the genome-wide expression level of 4-cell and 8-cell human embryos. For each window, the expression level was quantified Chung et al. (E and F) Box plots comparing the average intensity of H3K9me3-ChIP-seq (E) and DNaseI-seq (F) within FRR, PRR and RRR in different somatic cell types. ChIP-seq and DNaseI-seq data sets were obtained from the ENCODE projects (ENCODE Project Consortium, 2011).
Middle line in the colored space indicates the median, the edges indicate the 25th/75th percentiles, and the whiskers indicate the 2.5th/97.5th percentiles. *** p <0.001, ** p < 0.01.
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Supplemental Experimental Procedures
Mice B6D2F1/J (BDF1) mice were produced by crossing C57BL/6J females with DBA/2J males, and were used for the collection of both oocyte and somatic nuclear donor for SCNT. All animal experiments were approved by the Institutional Animal Care and Use Committee of Harvard Medical School.
In vitro transcription of human KDM4A mRNA
In vitro transcription was performed as described previously . Briefly, full length human KDM4A/JHDM3A cDNA was cloned into a pcDNA3.1 plasmid containing poly(A)83 at the 3' end of cloning site. The catalytic defective mutant form of KDM4A (H188A) was generated using PrimeSTAR mutagenesis kit (TAKARA # R045A). mRNA was synthesized using the mMESSAGE mMACHINE T7 Ultra Kit (Life technologies # AM1345). The synthesized mRNA was dissolved in nuclease-free water. The concentration of mRNA was measured by NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). Aliquots of mRNA were stored at -80°C until use.
Mouse SCNT and KDM4A mRNA injection
Mouse somatic cell nuclear transfer was carried out as described previously .
Briefly, both recipient MII oocytes and donor cumulus cells were collected from adult BDF1 female mice through superovulation by injecting 7.5 IU of pregnant mare serum gonadotropin (PMSG; Millipore # 367222) and 7.5 IU of human chorionic gonadotropin (hCG; Millipore # 230734). Fifteen to seventeen hours after the hCG injection, cumulus-oocyte complexes (COCs) were collected from the oviducts and treated briefly with Hepes-buffered potassium simplexoptimized medium (KSOM) containing 300 U/ml bovine testicular hyaluronidase (Calbiochem # 385931) to obtain dissociated MII oocytes and cumulus cells. Isolated MII oocytes were enucleated in Hepes-buffered KSOM medium containing 7.5 μg/ml of cytochalasin B (Calbiochem # 250233) by using Piezo-driven micromanipulator (Primetech # PMM-150FU).
The nuclei of donor cumulus cells were injected into the enucleated oocytes. After 1h incubation in KSOM, reconstructed SCNT oocytes were activated by incubating in Ca-free KSOM containing 2.5 mM SrCl2 and 5 μg/ml cytochalasin B for 1 h, and further cultured in KSOM with cytochalasin B for 4 h. Activated SCNT embryos were washed 5 hrs after the onset of SrCl 2 treatment (hours post activation, hpa) and cultured in KSOM in a humidified atmosphere with 5% CO 2 at 37.8°C. The SCNT embryos were injected with ~10 pl of water (control), 1500 ng/μl wild-type or mutant (H188A) human KDM4A mRNA at 5-6 hpa by using a Piezo-driven micromanipulator. Preimplantation developmental rates were analyzed by Student's T-test.
Preparation of human oocytes
The protocol for human oocyte experiments (CHA001) was approved by both the CHA Regenerative Medicine Institute (CHARMI) Stem Cell Research Oversight (SCRO) Committee and the Pearl Institutional Review Board (PIRB). Initial oocyte donor recruitment was performed via web-based advertisement as described previously . All donors were voluntary participants that were screened on the basis of their reproductive, medical, and psychological health according to the guidelines of the American Society for Reproductive Medicine (ASRM). Oocyte donors were financially reimbursed for their time, effort, loss of wages, travel related expenses, discomfort, and other related expenses associated with the donation processes pursuant to the guidelines established by ASRM.
Ovarian stimulation was carried out as described previously . Briefly, a combination of human recombinant follicle-stimulating hormone (rFSH, 225-300IU, Merck) and human menopausal gonadotropin (Menopur 75IU, Ferring) were used to stimulate ovary for 9-11 days with GnRH antagonist (Ganirelix acetate, Merck) suppression. Lupron 4mg was used to mimic the LH surge when 1 or 2 follicles reached 18 mm in diameter. All medications were administered through subcutaneous injections. Transvaginal oocyte retrieval was performed approximately 36 hours after the Lupron injection. The collected COCs were denuded with 50-80 IU/ml hyaluronidase (Sigma-Aldrich) within 1-2 hours after retrieval. Then, they were kept in Global medium supplemented with 10% serum protein supplement (SPS; Cooper Surgical) (IVF Online) until use.
Donated human IVF embryos
The IVF embryos used for this study were obtained from the patients who had the desired number of children after standard IVF procedures, and the remaining embryos were cryopreserved in storage for several years (2-6 years). All donors voluntarily donated their embryos (multicell cleavage stage) for researches by signing an informed consent form. The embryo donation program for the research was approved by CHA Gangnam Medical Center's IRB.
Human donor somatic cell preparation and characterization
To prepare human nuclear donor somatic cells, small pieces of abdominal skin (0.5 cm x 0.3 cm)
were biopsied under local anesthesia and washed 3 times in PBS supplemented with an antibiotic/antimycotic solution (anti-anti 1X, Invitrogen) to remove any possible contaminants.
All the somatic cell donors used in this study were AMD patients (AMD subtype: Central Areolar Choroidal Dystrophy). DFB-6 was derived from a 52-year old female. DFB-7 was derived from a 42-year old female. DFB-8 was derived from a 59-year old male.
The procedures for somatic nuclear donor cell preparation are essentially the same as previously described . Briefly, the skin explant was mechanically minced and treated with collagenase (type I, 200 unit/ml, Worthington-biochem) in DMEM supplemented with 10 μg/ml penicillin-streptomycin solution to dissociate the skin tissue. After incubation overnight, the dissociated cells were collected, washed twice and seeded onto 60-mm culture dishes containing DMEM (Invitrogen, with 10% FBS, 1% non-essential amino acids and 10µg/mL penicillin-streptomycin) solution at 37°C and 5% CO2. Once the cells reached 80% confluency, 1/2 of initial outgrowths were cryopreserved, and the remaining cells were kept passaged several times, with cells from each passage being cryopreserved. Frozen cells were subsequently thawed prior to SCNT and cultured in a 4-well dish (Nunc) until they reached confluency. They were then cultured in serum-starved DMEM (0.5% FBS) for 2-3 days to synchronize the cell cycle before use.
Derivation of human NTK-ESCs from KDM4A-assisted SCNT blastocysts
All expanded blastocysts were treated with acid Tyrode solution to remove the zona pellucida, then the entire blastocysts (without removing trophectoderm) were plated onto mitoticallyinactivated mouse fibroblasts (MEFs, Global Stem Inc.) in knockout-DMEM supplemented with Knockout Serum Replacement (10% SR, Invitrogen), FBS (10% Hyclone), bFGF (30ng/ml), human LIF (2000 units/ml, Sigma-Aldrich), and ROCK inhibitor (1uM, Sigma-Aldrich). The derivation medium was not changed for the next 3 days, then 1/2 medium was replaced with fresh medium without the ROCK inhibitor daily as previously described (Chung et al., 2008) .
After 3 passages, the amount of FBS was reduced to 2%, replacing it with SR. After 5 passages, the ES cells were cultured in DMEM/F12 supplemented with FGF (8 ng/ml, Invitrogen), SR (18%, Invitrogen), and FBS (2% Hyclone). After the 10 passages, the ES cells were maintained in DMEM/F12 supplemented with FGF (8 ng/ml) and 20% SR.
Preparation of 8-cell human embryos for ZGA analysis
The SCNT embryos used for ZGA analysis were generated using oocytes donated by a single healthy female (#64) and dermal fibroblast cells from an AMD patient (DFB-8). SCNT and IVF embryos were cultured up to late 8-cell stage, when the compaction of blastomeres is initiated, then they were treated briefly with acid Tyrode solution to remove zona pellucida. To prepare for the 8-cell SCNT embryo, oocytes from a single oocyte donor, and skin fibroblast cells from a single somatic nuclear donor were used. All the procedures are the same as described in the "Human SCNT procedure and KMD4A mRNA injection" section. Only embryos that reached the late 8-cell stage synchronically 74 hours post activation were collected and used for this experiment.
For preparation of the control IVF embryos, several donated early 8-cell stage IVF embryos were thawed and cultured for 5-7 hours to allow them to reach late 8-cell stage before being processed.
After removal of the zona pellucida, the denuded embryos were washed 3 times in PBS, loaded into RNAse and DNAse free PCR tubes, spin downed, and snap frozen in liquid nitrogen. Then, they were kept at -80°C until use. As controls, dermal fibroblast cells of somatic nuclear donors were also prepared. Those fibroblast cells were cultured in a 25 cm 2 flask in DMEM 10% FBS, and approximately 10,000 cells/donor were collected, snap frozen, and stored at -80oC until use.
Immunostaining
Mouse 1-cell SCNT embryos, undifferentiated human ESC colonies or differentiated embryoid bodied (EBs) were fixed by 4% paraformaldehyde (PFA) for 20 min at room temperature. After three washes with PBS containing 10 mg/ml BSA (PBS/BSA), the fixed samples were
